{
    "clinical_study": {
        "@rank": "168098", 
        "arm_group": [
            {
                "arm_group_label": "DA-9801 300mg", 
                "arm_group_type": "Experimental", 
                "description": "300mg of DA-9801 tablet is assigned at week 0 point and is taken for 8 continuous weeks, 3 times a day."
            }, 
            {
                "arm_group_label": "DA-9801 600mg", 
                "arm_group_type": "Experimental", 
                "description": "600mg of DA-9801 tablet is assigned at week 0 point and is taken for 8 continuous weeks, 3 times a day."
            }, 
            {
                "arm_group_label": "DA-9801 900mg", 
                "arm_group_type": "Experimental", 
                "description": "900mg of DA-9801 tablet is assigned at week 0 point and is taken for 8 continuous weeks, 3 times a day."
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo is assigned at week 0 point and is taken for 8 continuous weeks, 3 times a day."
            }
        ], 
        "brief_summary": {
            "textblock": "This is a Phase II dose-ranging study to evaluate the effectiveness and safety of DA-9801 in\n      the treatment of pain associated with diabetic neuropathy. Subjects will receive either\n      300mg, 600mg, 900mg or placebo, three times daily for eight weeks. During treatment, pain\n      score by Likert numerical rating scale, Patient Global Impression of Improvement (PGI-I) and\n      Change in Clinical Global Impression(CGI)are accessed to evaluate the effectiveness."
        }, 
        "brief_title": "Study of DA-9801 to Treat Diabetic Neuropathic Pain", 
        "condition": "Diabetic Neuropathies", 
        "condition_browse": {
            "mesh_term": [
                "Diabetic Neuropathies", 
                "Neuralgia"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  the age of 20 ~ 70\n\n          -  Type I or Type II Diabetes\n\n          -  HbA1c \u226411%\n\n          -  Patients with diabetic neuropathic pain for at least 3 months\n\n          -  Patients corresponding to average pain level of 4 points or more for 24 hours\n             evaluated with 11-point Likert scale\n\n        Exclusion Criteria:\n\n          -  neuropathic pain due to other causes or another stronger pain other than neuropathic\n             pain\n\n          -  abnormal in blood pressure, weight, ALT/AST, Serum creatinine\n\n          -  positive reaction in HIV, HBV, or HCV\n\n          -  experience of suicide try or Mental Illness Medical History\n\n          -  BDI(Beck Depression Inventory) grade exceeding 21 points chronic alcohol abuse\n             history"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "120", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 13, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01813799", 
            "org_study_id": "DA-9801"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "DA-9801 300mg", 
                    "DA-9801 600mg", 
                    "DA-9801 900mg"
                ], 
                "intervention_name": "DA-9801", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": "Diabetic Neuropathies", 
        "lastchanged_date": "August 12, 2013", 
        "location": {
            "contact": {
                "email": "pts@chonbuk.ac.kr", 
                "last_name": "Tae Seon Park, M.D., Ph.D.", 
                "phone": "82-63-250-1794"
            }, 
            "facility": {
                "address": {
                    "city": "Jeon-ju", 
                    "country": "Korea, Republic of", 
                    "zip": "561-712"
                }, 
                "name": "Chonbuk National University Hospital"
            }, 
            "investigator": {
                "last_name": "Tae Seon Park, M.D., Ph.D.", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "4", 
        "official_title": "Phase 2 Clinical Study to Evaluate DA-9801 Tablet's Effectiveness and Safety and to Decide Optimal Volume for Neuropathic Pains With Diabetic Neuropathy Patients as the Target", 
        "overall_contact": {
            "email": "irb@cuh.co.kr", 
            "last_name": "Tae Seon Park, M.D., Ph.D.", 
            "phone": "82-2-63-250-2154"
        }, 
        "overall_official": [
            {
                "affiliation": "The Catholic University of Korea", 
                "last_name": "Bongyeon Cha, M.D.", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Catholic University Yeouido St. Mary's Hopspital", 
                "last_name": "Hyeok Sang Gwon, M.D.", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Gangdong Kyunghee University Hospital", 
                "last_name": "Inkyung Jeong, M.D.", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Daegu Catholic University Medical Center", 
                "last_name": "Ji Hyeon Lee, M.D.", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Kyungbook National University Hospital", 
                "last_name": "Jeong Guk Kim, M.D.", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Busan National University Hospital", 
                "last_name": "In Ju Kim, M.D.", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Seoul National University Hospital", 
                "last_name": "Young Min Cho, M.D.", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Yonsei University Wonju Christian Hospital", 
                "last_name": "Chun Hee Jung, M.D.", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Inje University", 
                "last_name": "Jyeong Hyeon Park, M.D.", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Inha University Hospital", 
                "last_name": "Mun Seok Nam, M.D.", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Chonnam National University Hospital", 
                "last_name": "Dong Hyeok Cho, M.D.", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "SMG-SNU Boramae Medical Center", 
                "last_name": "Min Kyong Moon, M.D.", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Sejong Hospital", 
                "last_name": "Chong Hwa Kim, M.D.", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Jeju National University Hospital", 
                "last_name": "Kwan Pyo Ko, M.D.", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "South Korea: Korea Food and Drug Administration (KFDA)", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "August 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Average pain score reduction compared to baseline", 
            "safety_issue": "No", 
            "time_frame": "8 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01813799"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Average pain score", 
                "safety_issue": "No", 
                "time_frame": "8 weeks"
            }, 
            {
                "measure": "Most severe pain score", 
                "safety_issue": "No", 
                "time_frame": "8 weeks"
            }, 
            {
                "measure": "Overnight pain score", 
                "safety_issue": "No", 
                "time_frame": "8 weeks"
            }, 
            {
                "measure": "Patient global impression of improvement", 
                "safety_issue": "No", 
                "time_frame": "8 weeks"
            }, 
            {
                "measure": "Clinical global impression", 
                "safety_issue": "No", 
                "time_frame": "8 weeks"
            }, 
            {
                "measure": "Average weekly rescue medication use", 
                "safety_issue": "No", 
                "time_frame": "8 weeks"
            }
        ], 
        "source": "Dong-A Pharmaceutical Co., Ltd.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Dong-A Pharmaceutical Co., Ltd.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2011", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "August 2013"
    }
}